Efficacy of periarticular tranexamic acid administration in elderly individuals with femoral neck fracture undergoing hemiarthroplasty: A randomized controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR202102090010

Enrollment

Registered

2021-02-09

Start date

2021-02-11

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Efficacy in blood loss reducing of peri-articular TXA injection in patients who have undergone hemiarthroplasty. Tranexamic acid, Periarticular injection, Hip hemiarthroplasty, Blood loss

Interventions

Peri-articular Tranexamic Injection 1000 mg Dilute with Sterile Normal Saline up to 50 ml Inject at 5 site periarticular 10 ml/site 1. Labrum 2. Joint capsule 3. Adductor muscle group : Adductor magnu

Experimental Drug,No Intervention Drug

Peri-articular Tranexamic Injection,No Peri-articular Tranexamic Injection

Eligibility

Sex/Gender

All

Age

40 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patient with femur neck fracture who undergoing bipolar hemiarthroplasty 2. Age 40 - 90 years old 3. No history of surgical fixation of the affected femur neck 4. Low energy trauma

Exclusion criteria

Exclusion criteria: 1. Preoperative hemoglobin < 10 g/dL or a platelet count < 140,000 /uL3 2. Renal Insufficiency ( Defined by creatinine clearance < 30 mL/min ) 3. Previous unprovoked and/or recurrent deep venous thrombosis or pulmonary embolism 4. Recent myocardial infarction , cerebrovascular event , or provoked deep venous thrombosis or pulmonary embolism within 30 days , Coronary stent placement with in 6 month 5. On oral contraceptives pill or drug with drug-interaction ie : Thrombin , Hemocoagulase , Batroxobin , Eptacog-alfa 6. On Anti-coagulants 7. Hypercoagulable state 8. Intolerance or allergy to any drug prescribed in the study 9. Refusal to participate

Design outcomes

Primary

Measure	Time frame
Number of patients received transfusion (%) 3 days postoperative Percentrage,Number of blood units transfused 3 days postoperative Units,Calculated blood loss 3 days postoperative Calculation from formula ,Intraoperative blood loss Postoperative Millimetre,Hemoglobin drop post-op day 3 3 days postoperative g/dL,Hemoglobin drop post-op day 1 1 day postoperative Laboratory result	—

Secondary

Measure	Time frame
Tranexamic acid-related adverse effects 3 days postoperative Postoperative Recording,Postoperative wound complications 3 days postoperative Postoperative Recording	—

Countries

Thailand

Contacts

Public ContactAthip Kongklam

Faculty of Medicine Vajira Hospital, Navamindradhiraj University

athip_3@hotmail.com66819010614

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026